NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Professor Paul Mulholland clinical studies in development:

July 18, 2024

1. Feasibility Phase II study of Standard of Electro-hyperthermia plus Standard of Care
2. Feasibility Phase II study Checkpoint inhibitor prior to Standard of Care in Glioblastoma
3. Following the feasibility studies: Phase II study of Checkpoint inhibitor plus Electro-hyperthermia
4. Citadel -123 Plus Electro-hyperthermia

Citadel- 123 = A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I- ATT001) directly administered in subject with relapsed glioblastoma.

Launching Event of Oncothermia in the Philippines - Dr. Paul MULHOLLAND
min. 16.50

https://www.neurooncologycare.co.uk/?fbclid=PAZXh0bgNhZW0CMTEAAab8lJFAfGcGLOPBpKjo2ICb75PndBJBLJvlPudf51AVRlYHWyNviXzx5XU_aem_5x58Z1Dfd4x9nzPD1nTuYw

https://www.instagram.com/ldn_immunotherapy/